Seattle, Wash., August 24, 2021 鈥� 海角社区, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of Greg Sargen to its Board of Directors.
鈥淚 am thrilled to welcome Greg to Umoja鈥檚 Board of Directors. Greg鈥檚 extensive executive experience, as well as his financial and accounting expertise within the biopharmaceutical industry, will be an important asset to Umoja,鈥� said Andy Scharenberg, M.D., co-founder and CEO of Umoja. 鈥淲e are fortunate to have Greg join our board during an exciting period of growth for the company as we continue accelerating our integrated pipeline of in vivo immunotherapies to the clinic.鈥�
With over 30 years of financial experience, Mr. Sargen most recently served as Chief Financial Officer and Executive Vice President of Corporate Development and Strategy at Cambrex Corporation. Prior to Cambrex, he served as Executive Vice President and Chief Financial Officer at Expanets, Vice President of Finance in the Chemicals Manufacturing Division of Fisher Scientific, and held executive positions with Merck, Heat and Control, and Deloitte & Touche. In addition to his role at Umoja, he also serves on the boards of Protara Therapeutics, Avid Bioservices, and Kindeva Drug Delivery. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the University of Pennsylvania as well as a B.S. in Accounting from Pennsylvania State University.
鈥淯moja鈥檚 integrated suite of in vivo technologies holds far-reaching potential to overcome the challenges that continue to plague the CAR-T therapy field,鈥� said Mr. Sargen. 鈥淚 look forward to working with this world-class team and leveraging my experience in service of reaching Umoja鈥檚 key milestones and bringing their therapies to market.鈥澛�
About 海角社区
海角社区, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient鈥檚 immune system in vivo. Founded based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, Umoja鈥檚 novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit .
###
Media Contact:
Marites Coulter
Verge Scientific Communications
mcoulter@vergescientific.com
+1 415.819.2214